Research & Development: Page 7
-
Biotech Spotlight
A biotech tackles drug discovery with transcription factor know-how
Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.
By Michael Gibney • Nov. 15, 2023 -
Can Sarepta’s Duchenne gene therapy still deliver on its promise?
For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.
By Kelly Bilodeau • Nov. 14, 2023 -
Trendline
Clinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
6 ways to improve clinical trial diversity — as shown by J&J
Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.
By Alexandra Pecci • Nov. 14, 2023 -
Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.
The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.
By Kelly Bilodeau • Nov. 13, 2023 -
Deep Dive
What if a CRISPR cure isn’t such an easy choice?
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023 -
Q&A
23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’
23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.
By Alexandra Pecci • Nov. 7, 2023 -
PharmaVoice 100
PharmaVoice 100s: Entrepreneurs
From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.
By Meagan Parrish • Nov. 3, 2023 -
How Big Pharma keeps the oncology engines hot with a host of strategies
From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.
By Michael Gibney • Nov. 2, 2023 -
Tools like ChatGPT can personalize clinical trials tech — if companies avoid the pitfalls
From hallucinations to data privacy, pharma looks to iron out the kinks of generative AI.
By Kelly Bilodeau • Nov. 1, 2023 -
Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says
Roivant Sciences CEO Matt Gline and Telavant CEO Frank Torti know Roivant’s position as buyers and sellers in the pharma industry, and they’re embracing those opportunities.
By Michael Gibney • Oct. 31, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Helen Sabzevari, an immunotherapy pioneer
Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.
By Meagan Parrish • Oct. 27, 2023 -
The 2023 Red Jacket honorees
This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.
By Meagan Parrish • Oct. 27, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Ken Getz, a champion of clinical trials
Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.
By Alexandra Pecci • Oct. 27, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Dr. Mark Goldberg, a clinical innovator
Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.
By Alexandra Pecci • Oct. 27, 2023 -
Biotech Spotlight
Cidara’s J&J-partnered immunotherapy could target flu and cancer
On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.
By Alexandra Pecci • Oct. 26, 2023 -
Patient groups have become a powerhouse in R&D. Here’s a look at their impact.
“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.
By Kelly Bilodeau • Oct. 25, 2023 -
Biotech Spotlight
An ‘inverse vaccine’ takes aim at autoimmune diseases
Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.
By Kelly Bilodeau • Oct. 23, 2023 -
PharmaVoice 100
PharmaVoice 100s: Clinical trial gurus
Industry leaders adopting cutting-edge technologies and strategies to change the paradigm of clinical research.
By Meagan Parrish • Oct. 19, 2023 -
From the rainforest to Wall Street — Jaguar Health’s big play for revitalization
A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.
By Kelly Bilodeau • Oct. 17, 2023 -
Has the science of anti-aging caught up with the dream of a longer life?
Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.
By Kelly Bilodeau • Oct. 16, 2023 -
Deep Dive
A decade later, biotech’s CRISPR revolution is still going strong
Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.
By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023 -
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.
By Michael Gibney • Oct. 12, 2023 -
Q&A
5 minutes with — IDEA Pharma’s Mike Rea
The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.
By Meagan Parrish • Oct. 11, 2023 -
Q&A // Biotech Spotlight
To close the pediatric innovation gap, this biotech has to think differently
Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.
By Alexandra Pecci • Oct. 11, 2023 -
Google bets on AI in the life sciences as ‘technology for a purpose’
A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.
By Alexandra Pecci • Oct. 10, 2023